Distalmotion secures USD 150 million to revolutionize robotic surgery

Distalmotion has secured USD 150 million to accelerate the FDA approval and the clinical expansion of its Dexter surgical robot in Europe.

Distalmotion, the Vaud-based medtech company responsible for the innovative Dexter surgical robot, has announced the first closing of its USD 150 million financing round, led by Revival Healthcare Capital. This substantial investment will pave the way for US Food and Drug Administration (FDA) approval and accelerate the expansion of clinical experience with Dexter in Europe.

Currently, Dexter is in day-to-day clinical use throughout Europe, performing a wide range of high-volume and complex procedures in general surgery, gynecology, and urology. Distalmotion’s CEO, Michael Friedrich, explains that Dexter enables “on-demand robotics,” providing surgeons with the benefits of both laparoscopic and robotic surgery while ensuring best-in-class minimally invasive care for patients. Surgeons can seamlessly switch between robotic and laparoscopic modalities during procedures, utilizing their preferred instruments for specialized tasks such as stapling.

One of Dexter’s main advantages is its accessibility, promoting wider adoption of robotic surgery across various clinical settings. The platform requires no additional infrastructure, easily integrates into existing clinical environments, and offers mobility for effortless sharing between departments. This allows institutions to expand their robotics programs across surgical disciplines, ultimately providing an enhanced standard of care for a broader range of patients in hospitals and surgery centers.

Prof. Dieter Hahnloser, head of colorectal surgery at Lausanne University Hospital, who performed the first general surgery procedure with Dexter in 2021, praised the robot for its advanced dexterity and open platform. Dexter’s compatibility with all 3D laparoscopes enables surgeons to leverage both current and future imaging innovations and choose the best tools and technology for each step of the procedure.

Paving the way for global expansion and revolutionizing robotic surgery

The latest financing round marks a significant milestone for Distalmotion, setting the stage for accelerated adoption of the Dexter surgical robot in hospitals worldwide. Rick Anderson, Chairman of Revival and Distalmotion, expressed pride in the global leadership team’s accomplishments in bringing Distalmotion’s technology to market and preparing for the company’s entry into the US market.

With this new funding, Distalmotion is poised to make a significant impact on the global surgical landscape by providing a versatile, accessible robotic platform that empowers surgeons and improves patient care. As the company pursues FDA approval and expands its clinical presence in Europe, Dexter’s innovative technology is set to revolutionize the field of robotic surgery.